Other Stories

Celltrion's COVID-19 treatment candidate to be given to high-risk patients before receiving approval Updated: 2021-01-14 17:02:37 KST

A COVID-19 treatment drug candidate from S. Korean firm Celltrion will be given to high-risk patients this month even before being granted approval as part of a separate clinical trial.
The Central Disaster Management Headquarters says the clinical trial will help determine whether the drug is effective against the new COVID-19 variant currently sweeping the UK and South Africa.
Meanwhile, South Korea's food and drug safety ministry will begin the first stage of a three-part review process on Sunday to ensure the drug's safety and efficacy.
Reporter :
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.